Cytokinetics axes lead drug after it implodes in a PhIII muscle trial for ALS, shares crater
Cytokinetics $CYTK lead muscle drug has crashed in a Phase III study for ALS.
The biotech reported this morning that tirasemtiv, designed to amp up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
